Abstract: The present invention relates to combinations comprising anti-human OX40L antibodies, new biomarkers of autoimmune or alloimmune diseases, and their use in various therapeutic methods.

Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.

Abstract: A majority of military casualties occur during the pre-hospital period. The cause of death is largely associated with massive traumatic bleeding that leads to organ damage due to sustained hypoxia. Currently, therapeutics are lacking at the point of injury to mitigate hypoxic damage and maintain the survivability of severe hemorrhage prior to reaching medical facilities. This invention addresses that by introducing a method of co-administering prolyl hydroxylase domain inhibitor (PHDi, MK-8617), anti-fibrinolytic agent (tranexamic acid), and bradykinin receptor antagonist (icatibant) as anti-hemorrhage agents in combination with resuscitation fluid treatment with colloid solution of 25% human albumin that has an advantage of relatively small volume requirement to maintain blood volume. In addition, a kit comprising anti-hemorrhage agents that can be easily carried to the battlefield is also provided here.

Abstract: The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.

Abstract: Provided herein are compositions, methods, and systems, comprising a programmable nucleic acid-guided nuclease and sequence-diverged donor sequences. The compositions and methods described herein facilitate editing of a targeted locus using a diverged sequence encoding for a functional protein product.

Abstract: The present disclosure provides for the treatment of cardiac diseases and disorders using in vitro-differentiated cardiomyocytes. Such methods can take advantage of both autologous and allogeneic pluripotent stem cells.

Abstract: This invention relates to in vitro and in vivo methods for engrafting liver cells, such as cholangiocytes, into a liver comprising administering the liver cells to the biliary tree of the liver. The liver cells may be in the form of aggregates and may be administered in the direction of decreasing biliary duct diameter. This may be useful for example for the treatment of an individual with a diseased or damaged liver.

Abstract: Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.

Abstract: The present disclosure provides a genetically engineered probiotic, including an exogenous expression cassette including a nucleotide sequence that encodes acetaldehyde dehydrogenase, wherein the probiotic intestinal bacterium is Escherichia coli strain Nissle 1917 (EcN), and uses thereof.

Abstract: Ammonia oxidizing microorganism preparations for delivery to the gastrointestinal system, kits including ammonia oxidizing preparations for delivery to the gastrointestinal system, and devices for administering ammonia oxidizing preparations to the gastrointestinal system are provided. Methods of introducing ammonia oxidizing microorganisms to the gastrointestinal system are provided. Methods of treating disorders, including gastrointestinal disorders and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided.

Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.

Abstract: The present invention relates to a composition comprising a Leuconostoc citreum strain or its culture as an active ingredient for preventing, improving or treating cholestatic liver injury, specifically primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). According to the present invention, since the composition exhibits excellent preventive and therapeutic effects on various cholestatic liver injuries, the composition can be usefully used as a composition for the treatment, prevention, improvement, or the like of cholestatic liver injury in humans or animals.

Abstract: Foods are described that provide controlled release of stabilized bacteria into the oral cavity on consumption, as well as their use. Such foods promote colonization of oral surface by the bacteria. Bacteria are selected to treat an oral condition, such as oral disease, halitosis, and/or stained enamel on consumption of the food.

Abstract: The present invention relates to a composition for use in the prevention of respiratory allergy, in particular allergic rhinitis, dust mite allergy and/or asthma. The invention also provides a kit comprising a combination of at least one polyphenol and at least one Bifidobacterium longum in one or more containers.

Abstract: The present disclosure provides compositions comprising Lactobacillus mucosae and soluble dietary fiber, and methods treatment related thereto, useful against metabolic syndrome and related diseases, disorders and morbidities.

Abstract: Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.

Abstract: Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

Abstract: Provided herein are methods for treating a health condition of a subject. The method may comprise detection of a microorganism in a sample from the subject and, subsequent to identification of the microorganism, generating a bacteriophage mixture comprising at least one bacteriophage capable of lysing the microorganism. One or more processes described herein may comprise shotgun metagenomic sequencing.

Abstract: The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as Parkinson's disease and Gaucher disease. The disclosure provides expression constructs comprising a transgene encoding beta-glucocerebrosidase, an inhibitory RNA targeting alpha-Synuclein, or a combination of the foregoing. The disclosure further provides methods of treating Gaucher disease, Parkinson's disease or other synucleinopathies by administering such expression constructs to a subject in need thereof.

Abstract: This invention relates to oncolytic viruses which are more resistant to neutralization and phagocytosis by immune systems, and methods for their preparation and treatment of disorders and diseases (such as cancer) with them. Described herein is an oncolytic Herpes Simplex Virus Type 1 (HSV-1) or Herpes Simplex Virus Type 2 (HSV-2) treated in immune sera that contain a high level of anti-HSV antibodies. In one preferred embodiment, the oncolytic virus includes an extracellular CD47 domain inserted into the N-terminus of a glycoprotein in order to inhibit phagocyte activity. The oncolytic virus is suitable for systemic administration for the treatment of cancer.

Abstract: A system for extracting substances from a source material includes a chamber assembly, one or more ultrasonic transducers, and one or more convective mixing mechanisms. The chamber assembly defines a chamber. The chamber is configured to hold source material and a solvent such that at least a portion of the source material is immersed in the solvent. The one or more ultrasonic transducers are configured to produce ultrasonic waves that impinge on at least a portion of the portion of the source material in the solvent. The one or more mixers are configured to mix at least a portion of the source material.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome improve the health and welfare of the animal. The present disclosure further relates to methods of modulating level of secondary metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level of tryptophan metabolism derivates.

Abstract: Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.

Abstract: This invention is related to the field of healthcare and especially to the treatment of memory disorders. The invention consists in the preparation of oral pharmaceutical formulations from an extract of flavonoids obtained from the species Talipairti elatum Sw., which acts improving the different types of memory, both in the short and long-term associated with different pathologies and with population aging in humans.

Abstract: The present disclosure relates to an infused botanical such as cannabis flowers that contain volatile and aromatic components, such as cannabinoids, terpenes, aldehydes, ketones and esters. A process of infusing these botanicals with terpenes, aldehydes, ketones and esters helps to improve flavor profile, aroma, and enhance bio-efficacy. The total terpene content of the infused botanical is between 1% to 15% w/w of the one or more botanicals in one embodiment, and between 2.5 to 3.5% w/w in another embodiment. These terpene content percentages fortify the infused botanical with higher terpene numbers that that which occurs naturally in one embodiment of the invention. In another embodiment, the invention restores or bolsters an initial terpene, aldehydes, ketone and ester profile. This invention can be used to infuse pre-rolled botanical cigarettes to extend shelf life and aroma, as well as to infuse rolling papers or cellulosic packages for botanicals and other products.

Abstract: The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis. The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis, as well as methods of medical treatment that include administering the pharmaceutical dosage forms.

Abstract: A pharmaceutical composition for prevention, palliation, or treatment of coronavirus infection and a food composition for prevention or alleviation of coronavirus infection, each composition containing black ginseng or a black ginseng extract as an active ingredient is provided. The composition exhibits excellent antiviral activity against corona viruses, which cause respiratory diseases, gastrointestinal diseases, liver diseases, brain diseases, etc., especially against corona virus-19 and thus, can be advantageously used in medications and foods for prevention, alleviation, or treatment of diseases caused by corona virus infection.

Abstract: A therapeutic composition includes a mother tincture of a leaf extract of a plant of the genus “Neurolaena” and the species “lobata” for use as a drug inhibiting human dihydroorotate dehydrogenase (DHODH).

Abstract: The present invention relates to an oral composition for use in the treatment and/or alleviation of symptoms such as pain and/or discomfort in a subject, such as pain or discomfort related to arthritis, or psoriasis. Such a treatment may further comprise application of a cannabinoid-comprising topical composition, such a CBD-comprising composition, such as a CBD-comprising hydroalcoholic gels. Different compositions comprising 3-O-Acetyl-11-Keto Beta Boswellic Acid, Curcuminoid, Vitamin C, and Vitamin D are disclosed.

Abstract: This invention relates to compositions and methods relating to a combination of naturally-occurring active ingredients useful for the regulation of kidney and excretory system function. The combination of active ingredients, comprising vitamin B6, vitamin E, iron, roundhead lespedeza, birch leaf, and red bilberry, improves the function of kidney structures. The present invention may be used to achieve lower blood nitrogen content, including help to eliminate creatinine, urea, uric acid, by improving glomerular filtration and thus delaying hemodialysis. The present invention may be used to achieve a pronounced anti-inflammatory effect on the kidneys and the urinary tract. The present invention may also be used on its own or as a part of conventional treatment for a long time or indefinitely.

Abstract: A composition for strengthening, developing, differentiating, or regenerating muscle, or preventing, ameliorating, or treating muscle loss or muscle fatigue includes a Schizonepeta tenuifolia extract as an effective component. The Schizonepeta tenuifolia extract as an effective component has the effects of restoring the viability of muscle cells, increasing the endurance time on the rotarod performance test, i.e., the holding time without falling off from the rod, compared to the control group, reducing the content of LDH, AST, and ALT in blood, increasing the grip strength, enhancing the expression amount of energy metabolism-related genes in muscle tissues, increasing the density of muscle fibers in muscle tissues, inducing a change in the fibroblast arrangement to have a well-organized structure, and reducing the expression of MuRF1 in muscle tissues, as compared to the control group.

Abstract: Compositions that contain enriched amounts of Withanolides are provided. Such compositions will include natural extracts of Ashwagandha (Withania somnifera), including whole plant extracts and/or root extracts, which have been supplemented with or contain elevated amounts of Withanolide A, Withanolide B, Withanolide D, Withaferin A, Withanoside IV, and/or Withanoside V. Methods for modulating GPX1, Nrf2, HO1, mTOR, TERT, ?-Catenin, and/or NF-?B using such Withanolide-enriched compositions are also disclosed, as well as using such Withanolide-enriched compositions to stimulate hair growth.

Abstract: A method for promoting chronic wound healing is provided, including administering an effective amount of Bletilla formosana (Hayata) Schltr. extract to a subject in need thereof, wherein the effective amount of Bletilla formosana (Hayata) Schltr. extract is 0.01 mg/kg-body weight to 100 mg/kg-body weight, and wherein the chronic wound including diabetic wound and Diabetic Foot Ulcer.

Abstract: The present disclosure relates to an herbal tea composition comprising a combination of at least nine bamboo tree leaves. The said bamboo tea blend is a natural hydrant and has high ratio of elements like copper, zinc, potassium, calcium, etc. The bamboo tea composition of the present disclosure has been found to be effective in improving stress management, diabetes, cardiovascular diseases, insomnia, anemia, osteoporosis, thyroid and in maintaining skin, brain, and bone health.

Abstract: The present invention relates to a composition for treating or ameliorating a liver disease and liver dysfunction, which includes a Zizania latifolia extract and a pharmaceutical composition or a food composition. The Zizania latifolia extract according to the present invention contains a high content of tricin, and thus may have an improved treatment, alleviation, amelioration, or prevention effect on liver diseases and liver dysfunction compared to those of conventional extraction methods.

Abstract: There is provided inter alia polypeptides such as antibodies or fragments thereof which bind to LPAR1.

Abstract: The present invention relates to a stable parenteral composition comprising Cetrorelix or a pharmaceutically acceptable salt thereof, which is ready-to-use and does not require reconstitution prior to administration.

Abstract: The present invention relates to a stable anti-angiogenic and anti-inflammatory pharmaceutical formulation and pharmaceutical combination for treatment and/or prevention of psoriasis. The present invention also relates to methods of preparation of such formulation and combination and uses thereof.

Abstract: The disclosure at hand concerns a pharmaceutical composition comprising Angioten-sin-(1-7) (Asp-Arg-Val-Tyr-Ile-His-Pro) for use in the treatment of coronavirus infection related diseases, wherein Angiotensin-(1-7) is administered in a formulation selected from the group consisting of intramuscular, transdermal, pulmonary, lingual, buccal, nasal or a combination of at least two members of said list. Furthermore, the disclosure relates to a pharmaceutical composition comprising Angiotensin-(1-7) in a pharmaceutical acceptable carrier.

Abstract: This invention relates to methods of administering oral octreotide therapy to a female subject relating to avoidance of combined oral contraceptives or use of a back-up method for contraception.

Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.

Abstract: The treatment of ovarian cancers (e.g., epithelial ovarian cancers), which are sensitive to polypeptides comprising an actinohivin or a variant thereof (e.g., AvFc), is described. Methods for killing ovarian cancer cells (e.g, epithelial ovarian cancer cells) are also provided.

Abstract: Apomers comprising apolipoprotein molecules complexed with amphipathic molecules and uses thereof for treating dyslipidemic and liver disorders.

Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: The present invention relates to a molecule for use in the treatment and/or prevention of viral infections caused by highly pathogenic coronaviruses, including Severe Acute Respiratory syndrome Coronavirus 2 (SARS-COV-2), or variants thereof, Severe Acute Respiratory syndrome Coronavirus ((SARS)-COV) and sarbecoviruses, said molecule being a mannose binding lectin (MBL) polypeptide, or a functional fragment, derivative, mutein or variant thereof, or an homologue having a percentage of identity with MBL polypeptide of at least 50, 60, 70, 80 or 90%, preferably for use in the treatment and/or prevention of 2019 Coronavirus disease (COVID-19).

Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

Abstract: The present disclosure provides a method of treating or preventing a disease or condition associated with fibrosis and/or diabetes in a subject in need thereof comprising subcutaneously administering to the subject one or more effective doses of a fibroblast growth factor 21 (FGF-21) polypeptide, e.g., FGF-21 conjugate, e.g., PEG-FGF-21.

Abstract: This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent.

Abstract: The present disclosure relates generally to methods of treating or preventing a tissue differentiation factor-associated disorder or disease, e.g., fibrosis, and methods of treating or preventing fibrosis in a subject using tissue differentiation factor related polypeptide (TDFRPs) in combination with an additional agent. The present disclosure also relates to compositions and pharmaceutical compositions comprising the TDFRPs and an additional agent.

Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising mRNA molecules encoding human granulocyte macrophage colony stimulating factor (GM-CSF) polypeptides and uses thereof in the treatment of Parkinson's Disease. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding human GM-CSF for use in such treatment.